Main menu Navigation ●Main page ●Contents ●Current events ●Random article ●About Wikipedia ●Contact us ●Donate Contribute ●Help ●Learn to edit ●Community portal ●Recent changes ●Upload file

●Create account ●Log in ●Create account ● Log in Pages for logged out editors learn more ●Contributions ●Talk

(Top) 1 See also 2 References 3 External links

Dipraglurant

Add links ●Article ●Talk ●Read ●Edit ●View history Tools Actions ●Read ●Edit ●View history General ●What links here ●Related changes ●Upload file ●Special pages ●Permanent link ●Page information ●Cite this page ●Get shortened URL ●Download QR code ●Wikidata item Print/export ●Download as PDF ●Printable version Appearance From Wikipedia, the free encyclopedia

Dipraglurant
Clinical data

ATC code	None
Identifiers
IUPAC name 6-Fluoro-2-[4-(2-pyridinyl)-3-butyn-1-yl]imidazo[1,2-a]pyridine
CAS Number	872363-17-2
PubChem CID	44557636
ChemSpider	25069676
UNII	CV8JZR21A1
CompTox Dashboard (EPA)	DTXSID90236230
Chemical and physical data
Formula	C₁₆H₁₂FN₃
Molar mass	265.291 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES c1ccnc(c1)C#CCCc2cn3cc(ccc3n2)F
InChI InChI=1S/C16H12FN3/c17-13-8-9-16-19-15(12-20(16)11-13)7-2-1-5-14-6-3-4-10-18-14/h3-4,6,8-12H,2,7H2 Key:LZXMUJCJAWVHPZ-UHFFFAOYSA-N

Dipraglurant (INN) (code name ADX-48621) is a negative allosteric modulator of the mGlu₅ receptor which is under development by Addex Therapeutics for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).^[1]^[2]^[3] As of 2014, it is in phase II clinical trials for this indication.^[1] Addex Therapeutics is also investigating an extended-release formulation of dipraglurant for the treatment of non-parkinsonian dystonia.^[4]

References[edit]

^ ^a ^b Martinez A, Gil C (29 July 2013). Emerging Drugs and Targets for Parkinson's Disease. Royal Society of Chemistry. pp. 255–. ISBN 978-1-84973-617-6.

^ Fox SH, Brotchie JM (8 October 2014). Levodopa-Induced Dyskinesia in Parkinson's Disease. Springer. pp. 323–. ISBN 978-1-4471-6503-3.

^ "Dipraglurant-ER for dystonia". Addex Therapeutics. Archived from the original on 2014-12-28. Retrieved 2014-12-28.

mGluR₄Tooltip Metabotropic glutamate receptor 4	Agonists: Glutamate L-AP4 LSP2-9166 PHCCC VU-001,171 VU-0155,041; Positive allosteric modulators: Foliglurax MPEP Antagonists: CPPG MAP4 MPPG MSOP MTPG UBP-1112
mGluR₆Tooltip Metabotropic glutamate receptor 6	Agonists: Glutamate L-AP4 Antagonists: CPPG MAP4 MPPG MSOP MTPG UBP-1112
mGluR₇Tooltip Metabotropic glutamate receptor 7	Agonists: AMN082 Glutamate L-AP4 LSP2-9166 Antagonists: CPPG MAP4 MMPIP MPPG MSOP MTPG UBP-1112 XAP044; Negative allosteric modulators: ADX71743
mGluR₈Tooltip Metabotropic glutamate receptor 8	Agonists: DCPG Glutamate L-AP4; Positive allosteric modulators: AZ12216052 Antagonists: CPPG MAP4 MPPG MSOP MTPG UBP-1112

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.